Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
ZLTQ's Cash to Debt is ranked higher than
87% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ZLTQ: No Debt )
ZLTQ' s 10-Year Cash to Debt Range
Min: 6.45   Max: No Debt
Current: No Debt

Equity to Asset 0.72
ZLTQ's Equity to Asset is ranked higher than
78% of the 439 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ZLTQ: 0.72 )
ZLTQ' s 10-Year Equity to Asset Range
Min: -5.35   Max: 0.89
Current: 0.72

-5.35
0.89
Interest Coverage No Debt
ZLTQ's Interest Coverage is ranked higher than
88% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 436.41 vs. ZLTQ: No Debt )
ZLTQ' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 27.23
M-Score: -1.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3.00
ZLTQ's Operating margin (%) is ranked higher than
64% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.96 vs. ZLTQ: -3.00 )
ZLTQ' s 10-Year Operating margin (%) Range
Min: -1082.23   Max: -12.76
Current: -3

-1082.23
-12.76
Net-margin (%) -3.25
ZLTQ's Net-margin (%) is ranked higher than
64% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.05 vs. ZLTQ: -3.25 )
ZLTQ' s 10-Year Net-margin (%) Range
Min: -1111.78   Max: -14.09
Current: -3.25

-1111.78
-14.09
ROE (%) -8.34
ZLTQ's ROE (%) is ranked higher than
61% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.08 vs. ZLTQ: -8.34 )
ZLTQ' s 10-Year ROE (%) Range
Min: -195.78   Max: -28.57
Current: -8.34

-195.78
-28.57
ROA (%) -5.95
ZLTQ's ROA (%) is ranked higher than
62% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.46 vs. ZLTQ: -5.95 )
ZLTQ' s 10-Year ROA (%) Range
Min: -103.26   Max: -15.33
Current: -5.95

-103.26
-15.33
ROC (Joel Greenblatt) (%) -64.11
ZLTQ's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.43 vs. ZLTQ: -64.11 )
ZLTQ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1849.11   Max: -406.02
Current: -64.11

-1849.11
-406.02
» ZLTQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ZLTQ Guru Trades in Q4 2013

Jim Simons 364,357 sh (New)
RS Investment Management 978,900 sh (New)
Chuck Royce 410,200 sh (-25.85%)
» More
Q1 2014

ZLTQ Guru Trades in Q1 2014

Steven Cohen 481,900 sh (New)
RS Investment Management 1,165,400 sh (+19.05%)
Chuck Royce Sold Out
Jim Simons 67,400 sh (-81.5%)
» More
Q2 2014

ZLTQ Guru Trades in Q2 2014

RS Investment Management 1,348,166 sh (+15.68%)
Steven Cohen 577,600 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

ZLTQ Guru Trades in Q3 2014

Paul Tudor Jones 11,126 sh (New)
Steven Cohen 635,700 sh (+10.06%)
RS Investment Management 1,170,166 sh (-13.2%)
» More
» Details

Insider Trades

Latest Guru Trades with ZLTQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 126.58
ZLTQ's Forward P/E is ranked higher than
81% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZLTQ: 126.58 )
N/A
P/B 17.80
ZLTQ's P/B is ranked higher than
54% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. ZLTQ: 17.80 )
ZLTQ' s 10-Year P/B Range
Min: 1.79   Max: 17.8
Current: 17.8

1.79
17.8
P/S 7.88
ZLTQ's P/S is ranked higher than
61% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. ZLTQ: 7.88 )
ZLTQ' s 10-Year P/S Range
Min: 0.17   Max: 7.88
Current: 7.88

0.17
7.88
EV-to-EBIT -245.50
ZLTQ's EV-to-EBIT is ranked higher than
56% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 75.24 vs. ZLTQ: -245.50 )
ZLTQ' s 10-Year EV-to-EBIT Range
Min: -266.2   Max: -2.8
Current: -245.5

-266.2
-2.8
Current Ratio 3.06
ZLTQ's Current Ratio is ranked higher than
73% of the 460 Companies
in the Global Medical Devices industry.

( Industry Median: 2.63 vs. ZLTQ: 3.06 )
ZLTQ' s 10-Year Current Ratio Range
Min: 1.09   Max: 8.26
Current: 3.06

1.09
8.26
Quick Ratio 2.38
ZLTQ's Quick Ratio is ranked higher than
75% of the 460 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. ZLTQ: 2.38 )
ZLTQ' s 10-Year Quick Ratio Range
Min: 0.78   Max: 7.87
Current: 2.38

0.78
7.87
Days Inventory 109.27
ZLTQ's Days Inventory is ranked higher than
82% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 159.92 vs. ZLTQ: 109.27 )
ZLTQ' s 10-Year Days Inventory Range
Min: 46.43   Max: 109.81
Current: 109.27

46.43
109.81
Days Sales Outstanding 35.87
ZLTQ's Days Sales Outstanding is ranked higher than
96% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 78.81 vs. ZLTQ: 35.87 )
ZLTQ' s 10-Year Days Sales Outstanding Range
Min: 8.79   Max: 237.12
Current: 35.87

8.79
237.12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 71.58
ZLTQ's Price/Net Cash is ranked higher than
83% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZLTQ: 71.58 )
ZLTQ' s 10-Year Price/Net Cash Range
Min: 3.49   Max: 103.21
Current: 71.58

3.49
103.21
Price/Net Current Asset Value 32.21
ZLTQ's Price/Net Current Asset Value is ranked higher than
78% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZLTQ: 32.21 )
ZLTQ' s 10-Year Price/Net Current Asset Value Range
Min: 3.12   Max: 30.64
Current: 32.21

3.12
30.64
Price/Tangible Book 19.52
ZLTQ's Price/Tangible Book is ranked higher than
59% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 7.51 vs. ZLTQ: 19.52 )
ZLTQ' s 10-Year Price/Tangible Book Range
Min: 2.32   Max: 14.86
Current: 19.52

2.32
14.86
Price/Median PS Value 2.97
ZLTQ's Price/Median PS Value is ranked higher than
55% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 1.24 vs. ZLTQ: 2.97 )
ZLTQ' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 2.32
Current: 2.97

0.09
2.32
Earnings Yield (Greenblatt) -0.40
ZLTQ's Earnings Yield (Greenblatt) is ranked higher than
66% of the 471 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ZLTQ: -0.40 )
ZLTQ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -0.4

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
ZELTIQ Aesthetics Inc was incorporated in the state of Delaware on March 22, 2005. In August 2011, the Company incorporated ZELTIQ Limited as a wholly-owned subsidiary in the United Kingdom to serve as its sales office for direct sales in Europe. The Company was founded to develop and commercialize a non-invasive product for the selective reduction of fat. On October 24, 2011, the Company completed its initial public offering, or IPO, of 8,050,000 shares of common stock, of which 7,743,000 shares were sold by the Company and 307,000 shares were sold by existing stockholders. The Company generates revenue from sales of CoolSculpting system and from sales of consumables to its customers. Its geographical region includes North America and International. The Company's first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. The Company manufactures and distributes its CoolSculpting system, including procedure packs, at its Dublin facility. The Livermore facility is used primarily for raw material storage. Through 2012 and the beginning of 2013, the Company has utilized OnCore Manufacturing LLC to manufacture and supply CoolSculpting system. ZELTIQ, CoolSculpting, and Company's logo are registered trademarks in the United States and in certain foreign countries. The design, development, manufacture, testing and sale of products are subject to regulation by governmental authorities, mainly FDA, and corresponding state and foreign regulatory agencies.
» More Articles for ZLTQ

Headlines

Articles On GuruFocus.com
CoolSculpting(R) Procedure Named "Best Fat-Reducing Treatment" by NewBeauty(R) Magazine Jan 27 2015 
Steven Cohen Buys New Drug Stock, Triples Investment in Medical Company Jan 25 2015 
New Year, New You, New Findings -- New Survey Reveals What Women Expect to Gain by Keeping New Year' Jan 21 2015 
ZELTIQ to Present at J.P. Morgan 33rd Annual Healthcare Conference Jan 13 2015 
ZELTIQ to Present at the J.P. Morgan 33rd Annual Healthcare Conference Jan 05 2015 
ZELTIQ(R) Aesthetics Named Fastest Growing Medical Device Company in North America by Deloitte's 201 Nov 13 2014 
ZELTIQ Announces Conference Call and Webcast of Third Quarter 2014 Financial Results to Be Held on O Oct 15 2014 
ZELTIQ(R) Aesthetics Showcasing Its CoolSculpting(R) Procedure at Plastic Surgery The Meeting 2014 Oct 15 2014 
4 Stocks To Buy, 1 To Avoid In 2012 Feb 18 2012 
Weekly CFO Sales Highlight: INFA, DHR, AN, SMTC, ZLTQ Oct 31 2011 

More From Our Partners
Will ZELTIQ (ZLTQ) Continue to Surge Higher? - Tale of the Tape Jan 28 2015 - ZACKS

More From Other Websites
[$$] Aesthetic-Laser Stocks Focus on More Upside Jan 30 2015
ZELTIQ® Receives FDA Clearance to Perform CoolSculpting® Procedure at Lower Temperatures for... Jan 29 2015
ZELTIQ® Receives FDA Clearance to Perform CoolSculpting® Procedure at Lower Temperatures for... Jan 29 2015
Will ZELTIQ (ZLTQ) Continue to Surge Higher? - Tale of the Tape Jan 28 2015
Will Mead Johnson (MJN) Disappoint Q4 Earnings Estimates? - Analyst Blog Jan 27 2015
Zeltiq Aesthetics Inc (ZLTQ), Five Prime Therapeutics Inc (FPRX): Point72’s Latest Bullish Moves Jan 27 2015
CoolSculpting(R) Procedure Named "Best Fat-Reducing Treatment" by NewBeauty(R) Magazine Jan 27 2015
Can Illumina (ILMN) Keep the Earnings Streak Alive in Q4? - Analyst Blog Jan 23 2015
Zeltiq Aesthetics Turns A Profit By Reducing Fat Jan 21 2015
Baxter's (BAX) PHOXILLUM Solutions Get FDA Nod for CRRT - Analyst Blog Jan 21 2015
New Year, New You, New Findings -- New Survey Reveals What Women Expect to Gain by Keeping New... Jan 21 2015
NetEase, HDFC Bank Follow Through On Recent Breakouts Jan 20 2015
Will ResMed (RMD) Surprise Earnings Estimates in Q2? - Analyst Blog Jan 20 2015
ZELTIQ Aesthetics (ZLTQ) Catches Eye: Stock Rises 6.2% - Tale of the Tape Jan 15 2015
ZELTIQ Reports Preliminary Fourth Quarter and Full Year 2014 Revenue Jan 13 2015
ZELTIQ to Present at J.P. Morgan 33rd Annual Healthcare Conference Jan 13 2015
Zeltiq Aesthetics Up 7% On Preliminary Q4 Revenue, 2015 Outlook Jan 13 2015
ZELTIQ AESTHETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 13 2015
ZELTIQ Reports Preliminary Fourth Quarter and Full Year 2014 Revenue Jan 13 2015
ZELTIQ to Present at the J.P. Morgan 33rd Annual Healthcare Conference Jan 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK